Skip to content
lifestyle.friendhood.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
UroGen Pharma Ltd.
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 5, 2026
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 5, 2026
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
July 29, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
July 8, 2026
UroGen Pharma to Present at Upcoming Investor Conferences
May 7, 2026
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
May 7, 2026
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
April 29, 2026
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
April 8, 2026
1
2
Next Page
→